VPRIV (velaglucerase alfa)
VPRIV (velaglucerase alfa) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy in patients with type 1 Gaucher disease. This lysosomal storage disorder is characterized by the accumulation of glucocerebroside in the liver, spleen, and bone marrow, which can lead to organomegaly and hematologic complications. The therapy serves as a replacement for the deficient endogenous enzyme to manage the clinical features of the disease.
How VPRIV Works
Gaucher disease is caused by a deficiency in beta-glucocerebrosidase, an enzyme responsible for breaking down the sphingolipid glucocerebroside into glucose and ceramide. Without sufficient enzyme activity, glucocerebroside accumulates in the lysosomes of macrophages, forming "Gaucher cells" that infiltrate various organs. Velaglucerase alfa acts by catalyzing the hydrolysis of this accumulated glucocerebroside. This process reduces the volume of stored lipid, addressing the underlying cause of organ enlargement and blood-related symptoms.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2010-02-26
- Routes
- INTRAVENOUS
- Dosage Forms
- INJECTABLE, POWDER
VPRIV Approval History
What VPRIV Treats
1 indicationsVPRIV is approved for 1 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Gaucher Disease
VPRIV Boxed Warning
HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement and after extended duration of therapy. Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., a...
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement and after extended duration of therapy. Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VPRIV and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full prescribing information for complete boxed warning. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. ( 5.1 ) Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. ( 5.1 ) If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VPRIV and immediately initiate appropriate medical treatment, including use of epinephrine. ( 5.1 )
VPRIV Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to VPRIV
3 of 4FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
9 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05529992 results posted | TAK-669-3001 2022-002323-35 | Ph 3 | completed | A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease |
| NCT04120506 | 0075-15-SZMC | Ph 4 | completed | Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) |
| NCT02574286 results posted | SHP-GCB-402 2015-001578-17 | Ph 4 | completed | Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease |
| NCT01614574 results posted | HGT-GCB-087 | Ph 3 | completed | Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease |
| NCT01842841 results posted | HGT-GCB-091 | Ph 3 | completed | Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease |
| NCT01685216 results posted | HGT-GCB-068 2012-003427-38 | Ph 1, Ph 2 | completed | Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease |
| NCT00553631 results posted | HGT-GCB-039 2007-002840-21 | Ph 3 | completed | Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease |
| NCT03702361 | 307-17-SZMC | Ph 4 | completed | Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease |
| NCT02528617 | 014-285 | Ph 4 | withdrawn | The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VPRIV FDA Label Details
Indications & Usage
FDA Label (PDF)VPRIV is indicated for the treatment of Gaucher Disease.
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement and after extended duration of ther...
Track VPRIV with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment